Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases

Kunlu Shen, Yu Gu, Yu Wang, Yajie Lu, Yueyan Ni, Huanhuan Zhong, Yi Shi and Xin Su

Abstract

Aims: The gene polymorphism of voriconazole metabolism–related liver enzyme is notable in East Asia population. It casts a significant influence on the rational use of voriconazole. We conducted this study to investigate the relationship between steady-state voriconazole trough concentration ($C_{\text{trough}}$) and adverse effects (AEs), especially hepatotoxicity.

Methods: We conducted a real-world study in the Jinling Hospital from January 2015 to June 2020. A total of 140 patients receiving voriconazole were enrolled in this study. The determination and scoring of voriconazole-associated hepatotoxicity were performed according to the Roussel Uclaf Causality Assessment Method scoring scale and the severity of hepatotoxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE).

Results: Elevated steady-state voriconazole $C_{\text{trough}}$ with concomitant AEs are the most common reason for dose adjustments during treatment. Compared with the group without any AEs, voriconazole $C_{\text{trough}}$ was significantly higher in the hepatotoxicity and neurotoxicity groups, and the incidence of both events showed an overall increasing trend with increasing voriconazole $C_{\text{trough}}$. Hepatotoxicity occurred in 66.7% of patients within 7 days of the first dose of voriconazole and 94.4% within 15 days of the dose. Steady-state voriconazole $C_{\text{trough}} > 3.61$ mg/l was associated with an increased incidence of hepatotoxicity (area under the curve = 0.645, p = 0.047). Logistic regression analysis showed that timely voriconazole dose adjustment was a predictor of attenuated hepatotoxicity after adjustment for confounders, but hepatotoxicity was not associated with voriconazole $C_{\text{trough}}$ measured at a single time point.

Conclusion: Hepatotoxicity and neurotoxicity correlate with voriconazole $C_{\text{trough}}$, and dose reduction in patients with elevated steady-state voriconazole $C_{\text{trough}}$ may prevent hepatotoxicity. In patients with early occurrence of hepatotoxicity, initial therapeutic drug monitoring (TDM) might predict the risk of hepatotoxicity. Follow-up TDM may be necessary to predict late onset hepatotoxicity.

Plain Language Summary

Safety of voriconazole for the treatment of pulmonary fungal diseases

Introduction: Several studies have suggested an association between the concentration of voriconazole in the blood and liver damage, but the evidence is weak. This study aimed to investigate relationships between voriconazole drug concentration and side effects and to analyze the factors affecting liver damage caused by voriconazole.

Methods: We conducted a study at the Jinling Hospital from January 2015 to June 2020, in which a total of 140 patients were finally enrolled.

Results: Voriconazole doses were adjusted in 44 patients due to abnormal voriconazole drug concentration or side effects, 32 patients reduced the dose and 8 patients increased
An elevated liver enzyme level was the most common cause for dose adjustment. After the first dose adjustment, most patients achieved the target drug concentration. A total of 18 patients were determined as probable or highly probable to have drug-induced liver injury from voriconazole. Voriconazole drug concentration was significantly higher in the liver damage and nervous system damage groups as compared with the group without any side effects, and most liver damage events occurred within 14 days of the first dose. Voriconazole drug concentration >3.61 mg/l was associated with an increased incidence of liver damage.

**Conclusion:** In this study, approximately one-third of patients with pulmonary fungal disease needed to adjust their dose after the standard dose of voriconazole treatment. The incidence of liver damage and nervous system damage showed an overall increasing trend with increasing voriconazole baseline concentrations. Initial therapeutic drug monitoring may be predictive of liver damage. Follow-up monitoring of liver enzymes may be needed.

**Keywords:** hepatotoxicity, safety, voriconazole, voriconazole trough concentration

**Received:** 9 January 2022; revised manuscript accepted: 4 September 2022.

**Introduction**

Therapeutic drug monitoring (TDM) has an important role in optimizing antifungal therapy and is routinely recommended for voriconazole in the Chinese Pharmacological Society guidelines, the British Society for Medical Mycology guidelines, and the Infectious Diseases Society of America guidelines. Different guidelines recommend different voriconazole trough concentration (C\textsubscript{trough}). This is most likely due to the different sources of evidence. Furthermore, the proportion of slow metabolic genotypes varies across countries. Asians have a higher proportion of slow metabolic genotypes compared with Caucasian or black populations, which suggests that Asian populations are at greater risk of exposure to high drug concentrations.

In adult clinical trials with voriconazole, the rates of AEs reported in the instructions differed from those in clinical practice. A study published by the French Network of Pharmacovigilance Centers analyzed the AEs associated with voriconazole during first 4 years of marketing. They found that abnormal liver function was noticeable as the most common adverse effect (AE). Other studies also showed that hepatotoxicity was the most common cause of voriconazole dose reduction or discontinuation. The results of a multicenter study by Hamada et al. showed that the rate of dose reduction or discontinuation due to hepatotoxicity was significantly higher than that of visual disturbances. Therefore, monitoring on hepatotoxicity is warranted compared with other AEs of limited duration or lower frequency.

Clinical trials of voriconazole have reported a varying incidence of hepatotoxicity, with abnormal liver enzyme elevations reported in the range of 1–69%. A large number of studies utilized the Common Terminology Criteria for Adverse Events (CTCAE) to assess hepatotoxic events. Meanwhile, there was a number of studies using different definitions. There is a risk that different definitions of AEs may cause underestimation or overestimation of the incidence of voriconazole toxic events and lead to errors in other conclusions related to them.

Controversy still exists regarding the correlation between voriconazole concentrations and hepatotoxicity. Several authors have reported a correlation between voriconazole C\textsubscript{trough} above 4.0 or 6.0 mg/l and hepatotoxicity. In determining drug-induced liver injury (DILI), several potential confounding factors need to be taken into account, such as patients’ previous liver function, the concomitant use of potentially hepatotoxic drugs, ethnic groups, and so on. Many studies failed to assess these factors.

In contrast, several prospective studies found no relationship between steady-state voriconazole C\textsubscript{trough} and hepatotoxicity. Pascual et al.
showed that although an increased incidence of hepatotoxic events were observed when voriconazole was >5.5 mg/l (8% versus 19%), the difference was not statistically significant; Park et al. suggested regular TDM with voriconazole reduced the incidence of discontinuation for AEs, but not the overall rate of AEs associated with voriconazole treatment.

There are no uniform criteria for determining DILI, and several methods have been developed to assess the causality of DILI. The Roussel Uclaf Causality Assessment Method (RUCAM) is a scale that reflects the likelihood that hepatotoxicity is induced by a drug by assigning different scores to the clinical, biochemical, serological, and radiological characteristics of hepatotoxicity based on the aggregated calculated scores.

In this study, we evaluated voriconazole dose adjustment regimens and target drug concentration attainment rates. RUCAM and CTCAE were used to measure voriconazole-induced hepatotoxicity. In order to support voriconazole’s rational clinical use, a correlation between toxic events (especially hepatotoxicity) and voriconazole steady-state \( C_{\text{trough}} \) was investigated.

**Methods**

**Patients**

The study included patients with a diagnosis of pulmonary fungal disease who visited Jinling Hospital and received intravenous or oral voriconazole (Pfizer) between 1 January 2015 and 30 June 2020. Inclusion criteria were (1) age \( \geq 18 \) years; (2) clinical diagnosis of patients with pulmonary fungal disease; (3) hospitalization for \( \geq 7 \) days; and (4) at least one steady-state voriconazole \( C_{\text{trough}} \) data obtained. Exclusion criteria were (1) combined definite hepatobiliary disease, such as all types of viral hepatitis, alcoholic liver disease, autoimmune liver disease, and primary biliary or sclerosing cholangitis; (2) hepatoprotective and enzyme-lowering therapy during the study period; (3) other drugs with definite hepatotoxicity (e.g. isoniazid, rifampicin, and docetaxel) were used in combination with voriconazole during voriconazole administration.

**Definition of research**

**Definition of voriconazole-induced hepatotoxicity**

The determination and scoring of voriconazole-associated hepatotoxicity were performed according to the RUCAM scoring scale modified by Danan and Teschke in 2016 (Table 3). First, the liver enzymes that were first measured to indicate the occurrence of DILI were included in the evaluation, and the \( R \) value was obtained by dividing the number of times the measured alanine aminotransferase (ALT) value was elevated compared with the upper limit of normal (ULN) by the number of times the measured alkaline phosphatase (ALP) value was elevated compared with the ULN of ALP: an \( R \) value \( \geq 5 \) indicated hepatocellular injury; an \( R \) value \( \leq 2 \) indicated cholestatic injury; and between 2 and 5 indicates mixed injury. Then, according to the \( R \) value corresponding to the type, the scale was used for the overall score: a score of 0 or below indicates that the drug is ‘excluded’ as the cause of hepatotoxicity; a score of 1–2 indicates ‘unlikely’; a score of 3–5 indicates ‘possible’; 6–8 points mean ‘probable’; and more than 8 points means ‘highly probable’. Based on the above definition, an RUCAM score of \( \geq 6 \) was considered in this study as probable or highly probable hepatotoxicity induced by voriconazole.

**Criteria for determining the severity of hepatotoxicity**

In this study, the severity of hepatotoxicity was graded according to CTCAE v.5.0. The general grading principles of CTCAE can be divided into five categories. The standard ULN values for total bilirubin (Tbil), ALP, gamma-glutamyl transpeptidase (GGT), aspartate aminotransferase (AST), and ALT in the laboratory of the Jinling Hospital Laboratory were 17.1 µmol/l, 150 U/l, 50 U/l, 40 U/l, and 40 U/l, respectively.

**Dose adjustment and therapeutic drug monitoring**

Therapeutic drug monitoring in this study was usually performed on day 4 or day 5 after the first dose of voriconazole administration. Clinicians typically used the following strategies for voriconazole dose adjustment (compliance rate \( \geq 93.2\% \)): in patients with high steady-state voriconazole
C<sub>trough</sub> over 5.5 mg/l with or without AE, 50% dose reduction was performed, followed by a further 50% dose reduction if the concentration remained high. If necessary, a direct discontinuation was adopted. On the contrary, 50% dose increase was adopted when steady-state voriconazole C<sub>trough</sub> were lower than 1 mg/l.

**Definition of steady-state voriconazole C<sub>trough**

For patients receiving a loading dose of intravenous or oral voriconazole (defined as voriconazole administered intravenously at 6 mg/kg q12h twice within first 24 h, followed by voriconazole administered intravenously at 4 mg/kg q12h or orally at 200 mg twice daily), C<sub>trough</sub> measured at or after 24 h of dosing was considered steady-state C<sub>trough</sub>. For patients who did not receive a loading dose, the values measured on or after day 6 of the treatment dose were considered steady-state C<sub>trough</sub>; for patients who reached steady-state C<sub>trough</sub> during treatment but had subsequent voriconazole dose adjustments for various reasons, the values measured on or after day 4 of the dose adjustment were considered steady-state C<sub>trough</sub>.33

**Genotyping and genotype classification**

Genotyping of three single nucleotide polymorphisms (SNPs) from stored DNA using the TaqMan analysis to identify major CYP2C19 alleles. rs4244285, rs4986893, and rs12248560 all had >98% call rates, defining the *2, *3, and *17 alleles, respectively.34 Patients were classified into metabolizer phenotypic categories using the established common consensus star allele nomenclature.35 Patients without a *2, *3, or *17 allele (i.e. *1/*1) were classified as ‘extensive metabolizers’, those with one *17 allele (i.e. *1/*17) and *17 homozygotes (i.e. *17/*17) were classified as ‘ultrametabolizers’. Patients with one *2 or *3 allele (i.e. *1/*2 or *1/*3) were classified as ‘intermediate metabolizers’, while patients with two *2 or *3 alleles (i.e. *2/*2, *2/*3, or *3/*3) were classified as ‘poor metabolizers’.

**Statistical analysis**

Normally distributed continuous data are expressed as mean value (± standard deviation, SD), non-normally distributed continuous data are expressed as median (the interquartile range, IQR), and categorical variables are expressed as counts (%). Owing to the non-normality of voriconazole concentrations, the Mann–Whitney U test was used to compare the mean values between the two sample groups. The Chi-square<sup>2</sup> test or Fisher’s exact test was used to compare the differences in frequency distribution between groups. Binary logistic regression analysis was used for multifactor analysis. Spearman’s method was used to study the correlation between variables. All the above analyses were performed using SPSS (version 25.0), and values were considered statistically significant when p value less than 0.05.

**Results**

**Baseline patient characteristics**

Of the 216 patients screened for this study, 76 patients were excluded. The reasons including age less than 18 years (n=5), unmeasured steady-state blood concentration data (n=48), and combined definite hepatobiliary disease prior to voriconazole treatment (n=23). Finally, a total of 140 patients were enrolled in the study analysis. According to the CYP2C19 genotype classification, there were 14 (32.6%) extensive metabolizers, 25 (58.1%) intermediate metabolizers, and 4 (9.3%) poor metabolizers with voriconazole C<sub>trough</sub> of 2.5 mg/l (1.0–7.5 mg/l), 6.7 mg/l (1.4–8.9 mg/l), and 4.4 mg/l (2.5–6.1 mg/l). The demographic and clinical characteristics of the study patients are shown in Table 1.

**Voriconazole dose adjustment regimen, reasons, and target therapeutic concentration attainment rate during treatment**

Forty-four (31.4%) patients required dose adjustment during voriconazole treatment (Table 2), of which 65.9% (29/44) patients adjusted dose within 1 week after the first dose, 72.7% (32/44) required a reduction of voriconazole dose, 18.2% (8/44) required an increase of voriconazole dose, and 9.1% (4/44) voriconazole discontinued due to adverse event. Voriconazole C<sub>trough</sub> over the upper threshold (63.3%, 28/44) was the most common cause of dose adjustments during treatment (Table 3). Of which, the dose was reduced in 11 patients to prevent AEs simply because of high voriconazole C<sub>trough</sub>. Up to 60.7% (17/28) of
Table 1. Clinical characteristics of the study population.

| Characteristics                         | Total (n = 140) |
|-----------------------------------------|----------------|
| Age, years                              | 63 (52~72)     |
| Sex, male/female                        | 102/38         |
| Weight, kg                              | 61.45 (± 12.4) |
| Smoking                                 | 32 (22.9%)     |
| Alcohol consuming                       | 19 (13.6%)     |
| Any comorbidity                         |                |
| Respiratory system disease              | 69 (49.3%)     |
| Cardiovascular disease                  | 40 (28.6%)     |
| Diabetes                                | 20 (14.3%)     |
| Malignancy                              | 20 (14.3%)     |
| Chronic kidney disease                  | 8 (5.7%)       |
| Hematologic malignancy                  | 3 (2.1%)       |
| Solid-organ transplantation             | 2 (1.4%)       |
| Others a                                | 58 (41.4%)     |
| CYPC219 genotypeb                       |                |
| *1*1                                    | 14 (32.6%)     |
| *1*2                                    | 23 (53.5%)     |
| *1*3                                    | 2 (4.7%)       |
| *2*2                                    | 2 (4.7%)       |
| *2*3                                    | 1 (2.3%)       |
| *3*3                                    | 1 (2.3%)       |
| Diagnosis                               |                |
| Proven                                  | 13 (9.3%)      |
| Probable                                | 97 (69.3%)     |
| Possible                                | 30 (21.4%)     |
| Mode of administration                  |                |
| Oral                                    | 64 (45.7%)     |
| Intravenous                             | 58 (41.4%)     |
| Sequential therapy                      | 52 (37.1%)     |

Table 1. (Continued)

| Other combination therapies             | Total (n = 140) |
|-----------------------------------------|----------------|
| Antibacterial drugs a                   | 109 (77.9%)    |
| Other antifungal drugs a                | 41 (29.3%)     |
| Antiviral drugs a                       | 2 (1.4%)       |
| Glucocorticoid therapy f                | 29 (20.7%)     |
| Proton-pump inhibitor                   |                |
| Pythonazole                             | 20 (14.3%)     |
| Lansoprazole                            | 20 (14.3%)     |
| Omeprazole                              | 16 (11.4%)     |
| Hospital stays                          | 16 (12.3~26)   |

Data are n (%), median (IQR), and mean value (SD).

aIncluding sinusitis (n = 1), allergic rhinitis (n = 1), chronic pulmonary heart disease (n = 2), lobectomy (n = 2), gallbladder stones (n = 3), postcholecystectomy (n = 2), duodenal ulcer (n = 1), splenectomy (n = 1), ulcerative colitis (n = 1), postoperative appendicitis (n = 1), hypothyroidism (n = 2), thyroid nodule (n = 1), anemia (n = 5), prostate enlargement (n = 7), bone and joint injury surgery (n = 6), brain atrophy (n = 1), postcataract surgery (n = 1), depression (n = 1), post-tonsillectomy (n = 1), posthysterectomy (n = 1), postoperative left lower extremity varicose veins (n = 1), rheumatoid arthritis (n = 3), ankylosing spondylitis (n = 3), systemic lupus erythematosus (n = 3), mechanized pneumonia (n = 3), interstitial pneumonia (n = 3), ANCA vasculitis (n = 1), mixed connective tissue disease (n = 1), nephrotic syndrome (n = 1), dry syndrome (n = 1), gout (n = 1), and hyperthyroidism (n = 1).

bSample size of 43 people.

cIncluding β-lactams (cephalosporins, imipenem, biapenem, piperacillin), quinolones (levofloxacin, moxifloxacin), tigecycline, glycopeptides (teicoplanin, vancomycin), linezolid, macrolides (clarithromycin, azithromycin), ornidazole, tetracyclines (minocycline), aminoglycosides (tetramiciline), and compound sulfamethoxazole.

dIncluding caspofungin, amphotericin B, and polymyxin.

eIncluding oseltamivir and ganciclovir.

fIncluding methylprednisolone and prednisone.

Table 1. (Continued)

patients had elevated voriconazole C\textsubscript{trough} with AEs, the combination was judged strongly correlated by clinicians, and the dose was subsequently reduced. The most common AE was elevated liver enzymes (42.9%, 12/28) followed by central neurotoxicity (10.7%, 3/28), gastrointestinal symptom (3.6%, 1/28), and rash (3.6%, 1/28).
84.1% (37/44) of patients underwent a single-dose adjustment to achieve the target $C_{\text{trough}}$ range (i.e. 1.5–5.5 mg/l). Only a small percentage of patients required more than twice dose adjustments (Table 4).

### Voriconazole-associated AEs and their correlation with steady-state $C_{\text{trough}}$

Of the 140 patients, 24.3% (34/140) had at least one or more AEs during voriconazole treatment. The most common AE was hepatotoxicity [12.9%; the median steady-state voriconazole $C_{\text{trough}}$ was 6.57 mg/l (IQR = 4.28–8.22 mg/l)], followed by the neurotoxicity group [7.1%; 8.00 mg/l (IQR = 4.73–10.54 mg/l)]. As shown in Figure 1, compared with the steady-state voriconazole $C_{\text{trough}}$ in 52 patients without any AEs during treatment, the visual impairment group (6.89 versus 4.17 mg/l; $p = 0.543$), the gastrointestinal AEs group (4.49 versus 4.17 mg/l; $p = 0.886$), cardiac-related AEs group (8.28 versus 4.17 mg/l; $p = 0.279$), and skin-related AEs group (3.89 versus 4.17 mg/l; $p = 0.538$) were not statistically significant differences. Steady-state $C_{\text{trough}}$, however, were significantly higher in the CTCAE ($\Delta \geq 2$) group (8.20 versus 4.17 mg/l; $p = 0.016$), hepatotoxicity group (6.57 versus 4.17 mg/l; $p = 0.031$), and neurotoxicity group (8.00 versus 4.17 mg/l; $p = 0.021$) (Figure 1).

### Voriconazole-induced hepatotoxicity

#### Voriconazole-induced hepatotoxicity staging and CTCAE grading

Based on RUCAM, a total of 18 patients (12.9%) were diagnosed as probable or highly probable to have DILI due to voriconazole, with a mean RUCAM score of 7.78 ($\pm 1.2$). By $R$ value type,
### Table 4. Clinical data of patients who received ≥2 voriconazole dose adjustments during treatment.

| Number | Baseline characteristics | CYPC219 genotype | Initial $C_{\text{trough}}$ (mg/l) | Reasons for dose adjustment | Dose adjustment program | Follow-up measurement of voriconazole concentration (mg/l) |
|--------|--------------------------|-------------------|-----------------------------------|-----------------------------|------------------------|---------------------------------------------------------|
| 1      | 70 years old, M, hospitalized for 32 days | *1*1 | 6.27 | Persistent high $C_{\text{trough}}$ | iv 0.2 g q12 h → iv 0.2 g qd → iv 0.2 g qod | 8.28, 4.98 |
| 2      | 62 years old, M, hospitalized for 24 days | *1*2 | 6.18, 6.5 | High $C_{\text{trough}}$ → low $C_{\text{trough}}$ | iv 0.2 g q12 h → iv 0.2 g qd → iv 0.2 g q12 h | 2.65, 0.64, 0.9 |
| 3      | 65 years old, M, hospitalized for 31 days | Untested | 6.64 | Elevated liver enzymes combined with elevated $C_{\text{trough}}$ → low $C_{\text{trough}}$ | iv 0.2 g q12 h → iv 0.15 g q12 h → iv 0.2 g q12 h | 0.8, 0.4 |
| 4      | 80 years old, M, hospitalized for 23 days | Untested | 10.6 | High $C_{\text{trough}}$ | iv 0.2 g q12 h → iv 0.2 g qd → 12 days off medication → iv 0.2 g qd | 9.8, 1.72 |
| 6      | 90 years old, M, hospitalized for 15 days | *2*2 | 7.8 | Elevated liver enzymes combined with elevated $C_{\text{trough}}$ | iv 0.2 g q12 h → iv 0.2 g qd → 6 days off medication | 4.02 |
| 7      | 36 years old, M, hospitalized for 36 days | Untested | 0.6 | Low initial $C_{\text{trough}}$ → rash combined with elevated $C_{\text{trough}}$ (manifests as flaky erythema) | iv 0.2 g q12 h → iv 0.2 g q8 h → iv 0.2 g q12 h | 8.5, 3.89, 4.24, 4.17 |

iv, intravenous drip; M, male; qd, administered once daily; q8 h, administered every 8 h; q12 h, administered every 12 h; qod, administered every other day.

Five patients (3.8%, 5/140) were hepatocellular injury type, five patients (3.8%, 5/140) were cholestasis type, and eight patients (5.7%, 8/140) were mixed type. According to the CTCAE grading, 27.8% (5/18) patients with hepatotoxicity were evaluated as grade 1, 38.9% (7/18) patients with hepatotoxicity were evaluated as grade 2, and 33.3% (6/18) patients with hepatotoxicity were evaluated as grade 3, and no patients with grade 4 were identified (Table 5).

**Incidence and timing of voriconazole-induced hepatotoxicity**

The incidence of hepatotoxicity and neurotoxicity increased with the steady-state voriconazole $C_{\text{trough}}$. Among the four groups, the incidence of hepatotoxicity and neurotoxicity ranged between 22.2% and 25% at steady-state voriconazole $C_{\text{trough}}$ of >4.0 mg/l. This was higher than the incidence at 4.0 mg/l (5–13.3%; Figure 2). There were 66.7% of patients who experienced hepatic toxicity within 7 days of the first voriconazole dose, and 94.4% within 15 days (Figure 3).

**Predictive thresholds for $C_{\text{trough}}$ in voriconazole-induced hepatotoxicity**

The analysis of receiver operating characteristic (ROC) showed that steady-state voriconazole $C_{\text{trough}}$ >3.61 mg/l were associated with an increased incidence of hepatotoxic events, with an area under the ROC curve of 0.645 (95% confidence interval (CI) = 0.534–0.757, $p = 0.047$; Figure 4).
Figure 1. AEs and voriconazole $C_{\text{trough}}$ of patients ($n=140$) during voriconazole treatment.

Table 5. Hepatotoxicity classification and CTCAE classification.

| RUCAM phenotype               | 0  | 1  | 2  | 3  | 4  |
|-------------------------------|----|----|----|----|----|
| Hepatocellular injury ($n=5$) | 0  | 0  | 3  | 2  | 0  |
| Cholestatic injury ($n=5$)    | 0  | 3  | 1  | 1  | 0  |
| Mixed injury ($n=8$)          | 0  | 2  | 3  | 3  | 0  |
| Total ($n$)                   | 0  | 5  | 7  | 6  | 0  |

CTCAE, Common Terminology Criteria for Adverse Events; RUCAM, Roussel Uclaf Causality Assessment Method. Data are $n$ (%).

**Multifactorial analysis of voriconazole-induced hepatotoxicity**

Reverse stepwise binary logistic regression models identified timely voriconazole dose adjustment as a protective factor in reducing hepatotoxicity [odds ratio (OR) = 0.189, 95% CI = 0.054–0.652, $p = 0.008$; adjusted OR = 0.190, 95% CI = 0.065–0.554, $p = 0.002$; Figure 5]. After adjusting for confounders, patients with elevated voriconazole $C_{\text{trough}}$ showed an increased risk of hepatotoxicity.
Figure 2. Correlation between the incidence of hepatotoxicity and central nervous system toxicity and voriconazole C\textsubscript{trough}.

Figure 3. The time interval between the onset of hepatotoxicity and the first dose of voriconazole.

(OR=1.088, \( p = 0.390 \)). The model had good goodness of fit [Hosmer and Lemeshow test Chi-square = 9.96, degree of freedom (df) = 1, \( p = 0.268 \); Nagelkerke \( R^2 = 0.187 \)], and its overall prediction power was 82.1%.

Correlation between voriconazole steady-state \( C_{\text{trough}} \) and liver enzymes
Spearman’s correlation analysis showed a positive correlation between steady-state voriconazole \( C_{\text{trough}} \) and TBil \((r=0.246)\), ALT \((r=0.270)\),
**Figure 4.** The optimal voriconazole $C_{\text{trough}}$ threshold for predicting the occurrence of hepatotoxicity.

**Figure 5.** Logistic regression analysis of voriconazole-induced hepatotoxicity.

AST ($r=0.405$), ALP ($r=0.276$), and GGT ($r=0.185$) levels ($p$ value < 0.05; Figure 6).

**Change in CTCAE classification of liver enzymes before and after voriconazole treatment**

Among 140 patients, TBil, ALT, AST, ALP, and GGT CTC $\geq$3 points were 1 (1%), 4 (3%), 3 (2%), 0 (0%), and 19 (17%) patients, respectively. TBil, ALT, AST, ALP, and GGT were elevated $\geq$2 points in 2 (1%), 11 (8%), 6 (4%), 2 (2%), and 32 (29%) patients, respectively. Considering that GGT was significantly higher than other liver enzymes after treatment, we further performed a subgroup analysis of the
correlation between GGT and voriconazole, and the results showed that steady-state voriconazole $C_{\text{trough}}$ ($p=0.002$) and voriconazole treatment duration ($p=0.026$) were independent positive predictors of $\Delta\text{CTC} (\text{GGT}) \geq 2$ (Table 6).

**Discussion**

There are no guideline recommendations for dose adjustment based on TDM results. Park et al.\textsuperscript{6} used a threshold of 1.0, 5.5, and 10.0 mg/l for adjusting dose based on the exposure data and the severity of the AEs. By following this strategy, the percentage of patients achieving their target therapeutic range increased from 49% to 77%. In this study, the majority of patients (84.1%, 37/44) only required one-time dose adjustment to reach the target concentrations (1.5–5.5 mg/l) with this regimen.

The Dutch Pharmacogenetics Working Group has provided more specific dose adjustment options for voriconazole based on pharmacogenomic treatment recommendations. Working group members suggested determining the initial dose of voriconazole in patients according to their CYP2C19 genotypes. For slow metabolizers, the dose should be reduced by 50% and for fast metabolizers, increased by 50%. Similarly, Zubiaur et al.\textsuperscript{36} used a physiology-based pharmacokinetic model to analyze the dose adjustment of voriconazole in a study and suggested that the standard dosing regimen in the current guidelines may only be applicable to the normometabolic phenotype.

Studies have shown that CYP2C19 nonwild (mutant) phenotypes are prevalent in Asian populations (60–70%), whereas this proportion is only about 30% in Caucasian and African.\textsuperscript{24} In this study, the intermediate metabolizers were also predominant in patients with CYP2C19 genotype, and the mean steady-state voriconazole $C_{\text{trough}}$ was higher than those of the extensive metabolizers. This may indicate that the dosing

---

**Figure 6.** Spearman’s rank-order correlation coefficient between liver enzymes and voriconazole $C_{\text{trough}}$ ($n=140$).
regimen of voriconazole needs to be adjusted for Chinese patients.

Of the 140 patients in this study, 44 (31.4%) experienced a dose adjustment during voriconazole treatment. The simultaneous elevation of C_{trough} and liver enzymes (42.9%) was the most common reason for the first voriconazole dose adjustment. Among them, 94% of patients had their voriconazole dose adjusted within 14 days, with the greatest proportion occurring between 4 and 7 days (45.5%, 20/44), which is likely due to routine monitoring after voriconazole administration. In addition, we observed that the dose was not adjusted in 10 patients with elevated C_{trough} and AEs, 13 patients with normal C_{trough} and 21 patients with elevated C_{trough} but no AEs. Thus, in clinical practice, therapeutic decisions are influenced by expected or observed toxicity as well as disease severity and host factors.37

| Influencing factors | △CTC (GGT) ≥2 | Single-factor analysis | OR (95% CI) | p  | Final model | OR (95% CI) | p  |
|---------------------|---------------|------------------------|-------------|----|-------------|-------------|----|
|                     |               |                        |             |    |             |             |    |
| Age                 |               |                        | 0.998 [0.962–1.035] | 0.998 | –           |             |    |
| Sex                 |               |                        | 0.765 [0.226–2.584] | 0.666 | –           |             |    |
| Smoking             |               |                        | 3.610 [0.712–18.303] | 0.121 | 3.287 [0.819–13.197] | 0.093 |
| Drinking            |               |                        | 0.273 [0.041–1.805] | 0.178 | 0.248 [0.048–1.279] | 0.096 |
| Antibacterial drug use |         |                        | 1.011 [0.221–4.629] | 0.989 | –           |             |    |
| Other antifungal drug use |   |                        | 0.488 [0.156–1.532] | 0.219 | –           |             |    |
| Glucocorticoid use  |               |                        | 1.415 [0.348–5.760] | 0.628 | –           |             |    |
| Acid-suppressing drug use |   |                        | 0.740 [0.299–2.395] | 0.061 | –           |             |    |
| Dose adjustment     |               |                        | 1.408 [0.465–4.266] | 0.545 | –           |             |    |
| Route of administration |          |                        |             |    |             |             |    |
| Intravenous         |               |                        | 0.534 [0.141–2.019] | 0.355 | –           |             |    |
| Oral                |               |                        | 1.025 [0.207–5.084] | 0.976 | –           |             |    |
| Any comorbidity     |               |                        |             |    |             |             |    |
| Cardiovascular disease |           |                        | 1.792 [0.476–6.756] | 0.389 | –           |             |    |
| Chronic Obstructive Pulmonary Disease | |                       | 0.647 [0.144–2.908] | 0.571 | –           |             |    |
| Diabetes            |               |                        | 0.829 [0.162–4.255] | 0.823 | –           |             |    |
| Chronic kidney disease |            |                        | 0.656 [0.077–5.555] | 0.699 | –           |             |    |
| Others              |               |                        | 0.763 [0.200–2.905] | 0.692 | –           |             |    |
| Steady-state voriconazole C_{trough} |   |                        | 1.276 [1.086–1.499] | 0.003 | 1.239 [1.079–1.423] | 0.002 |
| Duration of voriconazole treatment |       |                        | 1.041 [0.963–1.125] | 0.316 | 1.062 [1.007–1.120] | 0.026 |

△CTC, CTCAE grade difference of liver enzyme before and after treatment with voriconazole; CI, confidence interval; GGT, gamma-glutamyl transpeptidase; OR, odd ratio.
In a meta-analysis of 39 randomized controlled trials by Wang et al., the risk of discontinuing voriconazole due to elevated liver enzymes was high. There is still some controversy whether there is a correlation between hepatotoxicity and voriconazole C\textsubscript{trough}, however. Some studies have reported that steady-state voriconazole C\textsubscript{trough} above 4.0–6.0 mg/l are associated with an increased incidence of hepatotoxicity. Meanwhile, several other studies have also shown no correlation between steady-state voriconazole C\textsubscript{trough} and hepatotoxicity. A wide variation of hepatotoxicity is observed in different studies, which is likely due to the different study population, CYP2C19 genotype, disease severity, and dose and method of administration. The heterogeneity among studies may make it difficult to generalize the results based on population and definition criteria to all populations. A meta-analysis by Jin et al., which included 21 studies, showed a large difference in the incidence of voriconazole-associated liver injury between Asian and non-Asian studies. A reasonable downward adjustment of the upper target voriconazole concentration threshold recommended by current guidelines may be warranted in the Asian population.

In this study, compared with the steady-state voriconazole C\textsubscript{trough} in 52 patients without any AEs during treatment, there was no statistically significant difference in other AEs such as visual disturbances, except for the hepatotoxicity group and neurotoxicity group, which is consistent with some other studies. Using subject curve analysis, we determined that a steady-state C\textsubscript{trough} of 3.61 mg/l could predict hepatotoxicity with 94.4% sensitivity and 41.8% specificity. In other words, if the steady-state C\textsubscript{trough} was considered the only predictor of hepatotoxicity, 94.4% of patients would be identified, but 58.2% of the population would be overestimated. This led us to propose a more plausible hypothesis that increased voriconazole C\textsubscript{trough} may lead to an increased likelihood of toxic events. But, there is no perfect positive linear correlation with toxic events (especially hepatotoxicity) and that steady-state C\textsubscript{trough} at a single time point may not ideally predict the risk of hepatotoxic events.

Furthermore, logistic regression analysis was used to analyze the factors influencing voriconazole-associated hepatotoxicity, and the results indicated that timely voriconazole dose adjustment was an effective protection against hepatotoxicity. In other words, clinicians would actively reduce the dose or discontinue treatment based on the assessment of liver function to prevent hepatotoxicity.

Extracellular GGT acts as a membrane-bound zinc protein with a main function in glutathione recycling. Several studies have shown that GGT overexpression is associated with melanoma, and the association of long-term voriconazole use with photosensitivity has been confirmed by several studies.

We compared the CTC scores of patients before and after treatment, and the percentage of GGT in $\Delta$CTC $\geq$2 was significantly higher than that of the other enzymes and correlated with steady-state voriconazole C\textsubscript{trough} and length of voriconazole treatment during hospitalization. This is consistent with the observation that a certain proportion of patients requiring long-term oral voriconazole treatment showed isolated mild-to-moderate elevations in GGT, which may suggest the presence of high oxidative stress in this group of patients. Currently, only sporadic cases of the association between long-term voriconazole use and melanocytoma development exist, but due to the poor prognosis of melanoma complications, it is worthwhile to be alert to this indicator in clinical practice.

This study had some limitations. First, the CYP2C19 genotype polymorphism, which has been shown in several studies to affect voriconazole blood levels, was not identified in this study, which may be due to the small sample size tested for the genotype in this study. Second, this is a study of a specific Asian population and the findings may be only applicable to Asian populations.

In conclusion, this study found that around one-third of Chinese patients with pulmonary fungal disease required dose adjustment after regular doses of voriconazole. Hepatotoxicity was the most common cause of dose adjustment. In patients with early occurrence of hepatotoxicity, initial TDM might predict the risk of hepatotoxicity. Follow-up TDM is also required to predict late onset hepatotoxicity, however. GGT may be
used to reflect the level of oxidative stress in patients on long-term voriconazole.

Declarations

Ethics approval and consent to participate
All methods were carried out in accordance with the Declaration of Helsinki. The Ethics Committee of Jinling Hospital approved the research protocol (DZGZRZX-044). The need for informed consent was waived by the Ethics Committee of Jinling Hospital. None of the data could be traced back to an identifiable patient.

Consent for publication
Not applicable.

Author contributions
Kunlu Shen: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.
Yu Gu: Supervision; Writing – review & editing.
Yu Wang: Supervision; Writing – review & editing.
Yajie Lu: Writing – review & editing.
Yueyan Ni: Writing – review & editing.
Huanhuan Zhong: Writing – review & editing.
Yi Shi: Writing – review & editing.
Xin Su: Conceptualization; Investigation; Methodology; Project administration; Software; Supervision; Validation; Visualization; Writing – review & editing.

Acknowledgements
Not applicable.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Natural Science Foundation of China project (grant no. 82270019), the Natural Science Foundation of China project (grant no. 82070011) and the Key Project of Jiangsu Commission of Health (grant no. K2019004).

The fund had no role in the design of the study, collection, analysis, and interpretation of data and in writing the manuscript.

Competing interests
The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials
The data sets used and/or analyzed during this study are available from the corresponding author on reasonable request.

ORCID iD
Kunlu Shen https://orcid.org/0000-0001-8869-9044

References
1. Patterson TF, Thompson III GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016; 63: e1–e60.
2. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503–535.
3. Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69: 1162–1176.
4. Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. Ther Drug Monit 2018; 40: 663–674.
5. Eiden C, Peyrière H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French pharmacovigilance database. Ann Pharmacother 2007; 41: 755–763.
6. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55: 1080–1087.
7. Hamada Y, Ueda T, Miyazaki Y, et al. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and
visual symptoms: a multicentre study conducted in Japan. Mycoses 2020; 63: 779–786.

8. Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatoxicity at 12 weeks in lung transplant recipients. Am J Transplant 2012; 12: 1929–1935.

9. Wang JL, Chang CH, Young-Xu Y, et al. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 2010; 54: 2409–2419.

10. Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother 2016; 71: 1772–1785.

11. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New Engl J Med 2002; 346: 225–234.

12. Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents 2014; 44: 436–442.

13. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplantation 2009; 9: 2085–2091.

14. Solis-Muñoz P, López JC, Bernal W, et al. Voriconazole hepatotoxicity in severe liver dysfunction. J Infect 2013; 66: 80–86.

15. Levin MD, den Hollander JG, van der Holt B, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother 2007; 60: 1104–1107.

16. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571.

17. den Hollander JG, van Arkel C, Rijnders BJ, et al. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006; 57: 1248–1250.

18. Wang Y, Wang T, Xie J, et al. Risk factors for voriconazole-associated hepatotoxicity in patients in the intensive care unit. Pharmacotherapy 2016; 36: 757–765.

19. Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis 2014; 209: 1941–1948.

20. Xing Y, Chen L, Feng Y, et al. Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections. BMC Infect Dis 2017; 17: 798.

21. Common Terminology Criteria for Adverse Events (CTCAE), https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf

22. Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012; 56: 2371–2377.

23. Chu HY, Jain R, Xie H, et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis 2013; 13: 105.

24. Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009; 34: 91–94.

25. Amigues I, Cohen N, Chung D, et al. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 46–52.

26. Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89: 592–599.

27. Potoski BA and Brown J. The safety of voriconazole. Clin Infect Dis 2002; 35: 1273–1275.

28. Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis 2011; 15: e753–e758.

29. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–211.
30. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. *Hepatology* 2001; 33: 123–130.

31. Danan G and Teschke R. RUCAM in drug and herb induced liver injury: the update. *Int J Mol Sci* 2015; 17: 14.

32. VFEND (voriconazole) i.v., tablets and suspension label, 2019, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039, 021267s050,021630s029lbl.pdf

33. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. *Antimicrob Agents Chemother* 2002; 46: 2546–2553.

34. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. *New Engl J Med* 2010; 363: 1704–1714.

35. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacocoeigenetic and clinical aspects. *Pharmacol Ther* 2007; 116: 496–526.

36. Zubiaur P, Kneller LA, Ochoa D, et al. Evaluation of voriconazole CYP2C19 phenotype-guided dose adjustments by physiologically based pharmacokinetic modeling. *Clin Pharmacokinet* 2021; 60: 261–270.

37. Kyriakidis I, Tragiannidis A, Munchen S, et al. Clinical hepatotoxicity associated with antifungal agents. *Expert Opin Drug Saf* 2017; 16: 149–165.

38. Luong ML, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. *J Antimicrob Chemother* 2016; 71: 1786–1799.

39. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. *J Clin Pharmacol* 2006; 46: 235–243.

40. Gorski E, Esterly JS, Postelnick M, et al. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. *Antimicrob Agents Chemother* 2011; 55: 184–189.

41. Corti A, Duarte TL, Giommarelli C, et al. Membrane gamma-glutamyl transferase activity promotes iron-dependent oxidative DNA damage in melanoma cells. *Mutat Res* 2009; 669: 112–121.

42. Franzini M, Corti A, Lorenzini E, et al. Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells. *Eur J Cancer* 2006; 42: 2623–2630.

43. Giommarelli C, Corti A, Supino R, et al. Cellular response to oxidative stress and ascorbic acid in melanoma cells overexpressing gamma-glutamyltransferase. *Eur J Cancer* 2008; 44: 750–759.

44. Auffret N, Janssen F, Chevalier P, et al. [Voriconazole photosensitivity: 7 cases]. *Ann Dermatol Venereol* 2006; 133: 330–332.

45. Malani AN and Aronoff DM. Voriconazole-induced photosensitivity. *Clin Med Res* 2008; 6: 83–85.

46. Vöhringer S, Schrum J, Ott H, et al. Severe phototoxicity associated with long-term voriconazole treatment. *J Dtsch Dermatol Ges* 2011; 9: 274–276.